Ajes Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 29-12-2024
- Paid Up Capital ₹ 0.10 M
as on 29-12-2024
- Company Age 13 Year, 12 Days
- Last Filing with ROC 31 Mar 2024
- Revenue 214.49%
(FY 2023)
- Profit 629.67%
(FY 2023)
- Ebitda 473.43%
(FY 2023)
- Net Worth 39.14%
(FY 2023)
- Total Assets -3.93%
(FY 2023)
About Ajes Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Arun Sharma and Anupama Sharma serve as directors at the Company.
- CIN/LLPIN
U52311MP2011PTC027383
- Company No.
027383
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Dec 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Bhopal, Madhya Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Ajes Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arun Sharma  | Director | 27-Dec-2011 | Current |
| Anupama Sharma | Director | 27-Dec-2011 | Current |
Financial Performance of Ajes Pharmaceuticals.
Ajes Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 214.49% increase. The company also saw a substantial improvement in profitability, with a 629.67% increase in profit. The company's net worth Soared by an impressive increase of 39.14%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ajes Pharmaceuticals?
In 2023, Ajes Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ajes Pharmaceuticals?
Unlock and access historical data on people associated with Ajes Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ajes Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ajes Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
